Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy-Reference-Cited by-同舟云学术

Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy

Published:2022-05-04 Issue:1 Volume:29 Page:1335-1344
ISSN:1071-7544
Container-title:Drug Delivery
language:en
Short-container-title:Drug Delivery

Author:

Shi Fan¹,Liu Yanli¹,Zhou Xuexiao²,Shen Pei²,Xue Ran³,Zhang Min¹

Affiliation:

1. State Key Laboratory of Military Stomatology, Department of General Dentistry and Emergency, School of Stomatology, Air Force Military Medical University, Xi’an, China

2. School of Stomatology of Qingdao University, Qingdao, China

3. Department of Pharmacy, The First Affiliated Hospital of Xi ’an Jiaotong University, Chang’an District Hospital, Xi ’an, China

Funder

National Nature Science Foundation of China

Shaanxi Science and Technology Innovation Team Project

Publisher

Informa UK Limited

Subject

Pharmaceutical Science,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/10717544.2022.2069883

Reference49 articles.

1. Trastuzumab‐monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2‐positive human breast cancer

2. New insights into affinity proteins for HER2-targeted therapy: Beyond trastuzumab

3. ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies

4. FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer

5. Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In-depth characterization of a cysteine-linked ADC disitamab vedotin by multiple LC-MS analysis methods and cutting-edge imaged capillary isoelectric focusing coupled with native mass spectrometry;Journal of Chromatography A;2024-11

2. Molecular mechanisms of HER2-targeted therapy and strategies to overcome the drug resistance in colorectal cancer;Biomedicine & Pharmacotherapy;2024-10

3. Disitamab vedotin (RC48) long-term regimen in a post-nephroureterectomy patient with metastases: a case report;Frontiers in Oncology;2024-09-13

4. HER2-low gastric cancer: is the subgroup targetable?;ESMO Open;2024-09

5. Analysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival;Neuro-Oncology;2024-08-30